Louise Rodino-Klapac - Mar 6, 2023 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role: Head of R&D, CSO
Signature: /s/ Ryan Brown, as Attorney-in-Fact for Louise Rodino-Klapac
Stock symbol: SRPT
Transactions as of: Mar 6, 2023
Transactions value $: -$178,276
Form type: 4
Date filed: 3/8/2023, 07:00 PM
Previous filing: Mar 3, 2023
Next filing: Mar 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRPT	Common Stock	Tax liability	-$178K	-1.13K	-1.67%	$157.21	66.6K	Mar 6, 2023	Direct	F1
transaction	SRPT	Common Stock	Award	$0	+4.5K	+6.76%	$0.00	71.1K	Mar 6, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRPT	Stock Option (right to buy)	Award	$0	+27K		$0.00	27K	Mar 6, 2023	Common Stock	27K	$155.99	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.
F2	The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.
F3	Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.